Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.

Authors:
Shen J; Chowdhury S; Agarwal N; Karsh LI; Oudard S and 14 more

Journal:
Br J Cancer

Publication Year: 2023

DOI:
10.1038/s41416-023-02492-8

PMCID:
PMC10781967

PMID:
37951974

Journal Information

Full Title: Br J Cancer

Abbreviation: Br J Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria from Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi. NA reports consultancy to Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics and Seattle Genetics; and research funding to institution from Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda and Tracon. LIK reports consulting or advisory role for 3D Biopsy, Astellas, AstraZeneca, Bayer, Dendreon, Ferring, Janssen, Pfizer and Vaxiion; speakers’ bureau for Astellas, Bayer, Janssen, Pfizer, and Clovis; honoraria from Astellas, Bayer, Janssen, Pfizer and Dendreon; stock or other ownership from Swan Valley Medical; research funding from Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, BU Optics, CUSP, Dendreon, Epizyme, Exact Sciences, Ferring, FKD, Genentech/Roche, GenomeDX, Genomic Health, Janssen, Merck, Myovant, Nucleix, OncoCell MDx, Pfizer, Pharmtech/Very, Precision Med and QED; and travel, accommodations and expenses from Astellas, Bayer, Dendreon, Janssen and Pfizer. SO reports advisory roles for Astellas Pharma, Bayer, Bristol Myers Squibb, Eisai, Janssen, Merck Sharp & Dohme, Novartis, Pfizer and Sanofi; compensation for travel from Bayer, Bristol Myers Squibb, Eisai, Merck Sharp & Dohme, Novartis and Pfizer; honoraria from Astellas Pharma, Bayer, Bristol Myers Squibb, Eisai, Janssen, Merck Sharp & Dohme, Novartis, Pfizer and Sanofi; and research funding from Ipsen and Sanofi. BAG reports consulting fees from Blue Earth, Immunogen, Janssen, Pfizer and Sanofi. Susan Feyerabend has nothing to disclose. FS reports advisory roles for Astellas Pharma, AstraZeneca/MedImmune, Bayer, Janssen Oncology and Sanofi; honoraria from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Janssen Oncology and Sanofi; and research funding grants provided to his institution from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Pfizer and Sanofi. CMP reports consulting or advisory role for Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Dendreon, Janssen Oncology, Merck, Sun Pharma, Pfizer and Tolmar; speakers’ bureau for Astellas Pharma, Bayer, Dendreon, Janssen Oncology, Merck, Myovant Sciences, Pfizer, Sun Pharma and Tolmar; honoraria from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Dendreon, Janssen, Merck, Myovant Sciences, Pfizer, Sun Pharma and Tolmar; and research funding from Advantagene, Astellas Pharma, AstraZeneca, Bayer, Dendreon, Innocrin Pharma, Janssen Oncology, Merck and Pfizer. KNC reports consultancy to Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Essa, Janssen, Novartis, Merck, Pfizer, Point Pharma, Roche and Sanofi; research funding to institution from Astellas, Janssen and Sanofi; and honoraria from Astellas, AstraZeneca, Bayer, Janssen, Merck and Pfizer. EJS reports advisory roles for Fortis and Janssen Oncology; compensation for travel from Janssen; stock and interest in Fortis and Harpoon Therapeutics; honoraria from Janssen; and research funding from Janssen and Merck Sharp & Dohme. MRS reports advisory roles for Amgen, Bayer, Janssen Oncology, Lilly, Novartis and Pfizer; compensation for travel from Amgen, Bayer, Janssen and Lilly; and research funding from Bayer, Gilead Sciences and Janssen Oncology. JNG reports an advisory role for Exelixis; compensation for travel from Bayer, Clovis Oncology and Merck Sharp & Dohme; patents, royalties and intellectual property with Oncoresponse: Exceptional Responders; honoraria from Astellas, Bayer, Janssen Oncology and Medivation; and research funding from Bristol Myers Squibb, Janssen Oncology, Medivation, Merck Sharp & Dohme and Sanofi. SDBM, BR, AB, SAMC, KBB and SDM are employees of Janssen Research & Development and may hold stock in Johnson & Johnson. AB also reports stock ownership of AbbVie."

Evidence found in paper:

"Funding TITAN and SPARTAN were funded by Janssen Research & Development. The sponsor was involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review and approval of the manuscript. All the authors had access to the data, drafted the manuscript with input from the sponsor (Janssen), reviewed and approved the manuscript before submission, and made the decision to submit the manuscript for publication. Janssen Global Services, LLC provided funding for editorial assistance."

Evidence found in paper:

"Clinical trial registration TITAN (NCT02489318); SPARTAN (NCT01946204)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025